| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Justin Faden, Leslie Citrom. A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder. Schizophrenia research. 2024-01-30. PMID:38290941. |
clozapine is the "gold standard" pharmacologic treatment for the management of persistent agitation and aggression in people with schizophrenia and is consistently recommended by guidelines and reviews for this purpose. |
2024-01-30 |
2024-02-02 |
Not clear |
| Justin Faden, Leslie Citrom. A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder. Schizophrenia research. 2024-01-30. PMID:38290941. |
although clozapine is indicated for treatment-resistant schizophrenia based on its superior efficacy, studies have proposed that clozapine may have specific properties that ameliorate aggression and hostility that are distinct from its antipsychotic effects. |
2024-01-30 |
2024-02-02 |
Not clear |
| Justin Faden, Leslie Citrom. A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder. Schizophrenia research. 2024-01-30. PMID:38290941. |
a literature review was conducted on june 3, 2023, using the us national library of medicine's pubmed resource to identify articles focusing on clozapine for the treatment of aggression, violence, and/or hostility in patients with schizophrenia or schizoaffective disorder. |
2024-01-30 |
2024-02-02 |
Not clear |
| John M Kane, Georgios Schoretsanitis, Jose M Rubio, Christoph U Correl. Clozapine in treatment-resistant schizophrenia: Reflections from the Hallmark US clinical trial and beyond. Schizophrenia research. 2024-01-30. PMID:38290942. |
clozapine in treatment-resistant schizophrenia: reflections from the hallmark us clinical trial and beyond. |
2024-01-30 |
2024-02-02 |
Not clear |
| Po-Yu Chen, Chih-Chiang Chiu, Chin-Kuo Chang, Mong-Liang Lu, Cho-Yin Huang, Chun-Hsin Chen, Ming-Chyi Huan. Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study. Journal of psychopharmacology (Oxford, England). 2024-01-27. PMID:38279671. |
higher orexin-a levels are associated with treatment response to clozapine in patients with schizophrenia: a cross-sectional study. |
2024-01-27 |
2024-01-29 |
Not clear |
| Po-Yu Chen, Chih-Chiang Chiu, Chin-Kuo Chang, Mong-Liang Lu, Cho-Yin Huang, Chun-Hsin Chen, Ming-Chyi Huan. Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study. Journal of psychopharmacology (Oxford, England). 2024-01-27. PMID:38279671. |
clozapine is the primary antipsychotic (apd) for treatment-resistant schizophrenia (trs). |
2024-01-27 |
2024-01-29 |
Not clear |
| Maiko Watanabe, Fuminari Misawa, Hiroyoshi Takeuch. Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image Study. Journal of clinical psychopharmacology. 2024-01-26. PMID:38277504. |
real-world effectiveness of high-dose olanzapine and clozapine for treatment-resistant schizophrenia in japan: a retrospective bidirectional mirror-image study. |
2024-01-26 |
2024-01-29 |
Not clear |
| Maiko Watanabe, Fuminari Misawa, Hiroyoshi Takeuch. Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image Study. Journal of clinical psychopharmacology. 2024-01-26. PMID:38277504. |
clozapine is considered the gold standard medication for treatment-resistant schizophrenia (trs). |
2024-01-26 |
2024-01-29 |
Not clear |
| Liliana Dell'Osso, Chiara Bonelli, Benedetta Nardi, Federico Giovannoni, Cristiana Pronestì, Ivan Mirko Cremone, Giulia Amatori, Stefano Pini, Barbara Carpit. Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug. Brain sciences. vol 14. issue 1. 2024-01-26. PMID:38275523. |
the current literature globally highlights the efficacy of clozapine in several psychiatric disorders all over the world, with an fda indication for reducing the risk of repeated suicidal behavior in patients with schizophrenia or schizoaffective disorder. |
2024-01-26 |
2024-01-28 |
Not clear |
| Ting Yat Wong, Hao Luo, Jennifer Tang, Tyler M Moore, Ruben C Gur, Yi Nam Suen, Christy Lai Ming Hui, Edwin Ho Ming Lee, Wing Chung Chang, Wai Ching Yan, Eileena Chui, Lap Tak Poon, Alison Lo, Koi-Man Cheung, Chui Kwan Kan, Eric Yu Hai Chen, Sherry Kit Wa Cha. Development of an individualized risk calculator of treatment resistance in patients with first-episode psychosis (TRipCal) using automated machine learning: a 12-year follow-up study with clozapine prescription as a proxy indicator. Translational psychiatry. vol 14. issue 1. 2024-01-22. PMID:38253484. |
about 15-40% of patients with schizophrenia are treatment resistance (tr) and require clozapine. |
2024-01-22 |
2024-01-25 |
Not clear |
| Sam Mostafa, Reza Rafizadeh, Thomas M Polasek, Chad A Bousman, Amin Rostami-Hodjegan, Robert Stowe, Prescilla Carrion, Leslie J Sheffield, Carl M J Kirkpatric. Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia. CPT: pharmacometrics & systems pharmacology. 2024-01-20. PMID:38243630. |
virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia. |
2024-01-20 |
2024-01-22 |
Not clear |
| Sam Mostafa, Reza Rafizadeh, Thomas M Polasek, Chad A Bousman, Amin Rostami-Hodjegan, Robert Stowe, Prescilla Carrion, Leslie J Sheffield, Carl M J Kirkpatric. Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia. CPT: pharmacometrics & systems pharmacology. 2024-01-20. PMID:38243630. |
using a high virtualization mipd-vt approach (simcyp version 21), we predicted the steady-state clozapine concentration and clozapine dosage range to achieve a target concentration of 350 to 600 ng/ml in hospitalized patients with treatment-resistant schizophrenia (n = 11). |
2024-01-20 |
2024-01-22 |
Not clear |
| Marcin Siwek, Adrian Andrzej Chrobak, Aleksandra Gorostowicz, Patrycja Król, Dominika Dude. Cariprazine augmentation of clozapine in schizophrenia-a retrospective chart review. Frontiers in pharmacology. vol 14. 2024-01-19. PMID:38239199. |
the aim of our study was to evaluate the efficacy of cariprazine augmentation of clozapine in treatment-resistant schizophrenia in a retrospective chart review. |
2024-01-19 |
2024-01-21 |
Not clear |
| Marcin Siwek, Adrian Andrzej Chrobak, Aleksandra Gorostowicz, Patrycja Król, Dominika Dude. Cariprazine augmentation of clozapine in schizophrenia-a retrospective chart review. Frontiers in pharmacology. vol 14. 2024-01-19. PMID:38239199. |
our study presents a thorough clinical description of the largest number of treatment-resistant schizophrenia patients medicated using cariprazine augmentation of clozapine in a "real-world" setting. |
2024-01-19 |
2024-01-21 |
Not clear |
| Roshan Poudel, Barron Lerne. The Tarnished Legacy of a Wonder Drug: Revisiting the Complicated History of Clozapine. Harvard review of psychiatry. vol 32. issue 1. 2024-01-05. PMID:38181102. |
anecdotal evidence of superior efficacy and lack of extrapyramidal symptoms in treating schizophrenia made clozapine a promising therapy in the united states during the early 1970s. |
2024-01-05 |
2024-01-08 |
Not clear |
| Floor C E Groenewald, Rob M Ko. Side effects of clozapine in older adults with treatment-resistant schizophrenia compared to younger adults. International journal of geriatric psychiatry. vol 39. issue 1. 2024-01-05. PMID:38180349. |
side effects of clozapine in older adults with treatment-resistant schizophrenia compared to younger adults. |
2024-01-05 |
2024-01-07 |
Not clear |
| Floor C E Groenewald, Rob M Ko. Side effects of clozapine in older adults with treatment-resistant schizophrenia compared to younger adults. International journal of geriatric psychiatry. vol 39. issue 1. 2024-01-05. PMID:38180349. |
to study the differences in side effects of clozapine between older adults aged ≥55 years and younger adults aged 18-55 years with treatment-resistant schizophrenia. |
2024-01-05 |
2024-01-07 |
Not clear |
| Kilian Lommer, Franziska Tutzer, Alex Hofe. Rhabdomyolysis during adjunctive treatment with cariprazine in a clozapine-resistant schizophrenia patient. International clinical psychopharmacology. 2024-01-03. PMID:38170806. |
we report the case of a 49-year-old male treatment-resistant schizophrenia patient, whose treatment with clozapine and sertraline was supplemented with cariprazine 1.5 mg/day while regularly presenting for electroconvulsive therapy. |
2024-01-03 |
2024-01-06 |
Not clear |
| Aslihan Aksar, Justina Lutz, Elias Wagner, Wolfgang Strube, Jurjen J Luykx, Alkomiet Hasa. Vaccination and clozapine use: a systematic review and an analysis of the VAERS database. European archives of psychiatry and clinical neuroscience. 2024-01-02. PMID:38165458. |
among the original articles, two studies provided data on the association between clozapine use and antibody responses to vaccination, both indicating that clozapine use in schizophrenia may be associated with reduced levels of immunoglobulins. |
2024-01-02 |
2024-01-05 |
Not clear |
| Michelle Iris Jakobsen, Stephen Fitzgerald Austin, Ole Jakob Storebø, Jimmi Nielsen, Erik Simonse. Non-prescribing of clozapine for outpatients with schizophrenia in real-world settings: The clinicians' perspectives. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-12-22. PMID:38135678. |
non-prescribing of clozapine for outpatients with schizophrenia in real-world settings: the clinicians' perspectives. |
2023-12-22 |
2023-12-25 |
Not clear |